In this study, we examined the effects of a novel PPAR-γ agonist, MEKT1, on Pomc expression/ACTH secretion using murine pituitary corticotroph tumor-derived AtT20 cells and compared them with rosiglitazone and pioglitazone. Here, POMC is linked to neoplasm.